Scalable Solutions Through kojoX™
Building a Biomanufacturing Ecosystem for Supply Agility Starts as Early as Cell Line Development
The global demand for biopharmaceuticals has the potential to outpace existing capacity, and across the globe substantial investments are being directed towards expanding the biomanufacturing capacity of Contract Development and Manufacturing Organizations (CDMOs). FUJIFILM Biotechnologies recognizes that constructing new facilities is insufficient to address the complex supply challenges facing the industry. As such, our unprecedented capital investments of >$8bn to expand capacity are just one of the vital means we have in place to improve patient access. Going beyond expansions, we have deployed a holistic, globally harmonized operational ecosystem that we call kojoX.